Patent Ductus Arteriosus Response to Treatment by Course and Associations with Perinatal and Clinical Factors
- 13 May 2023
- journal article
- research article
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 41 (S 01) , e1759-e1768
Abstract
Objective The objective of this study is to examine patent ductus arteriosus (PDA) response by treatment course and investigate associations with postmenstrual age (PMA), chronological age (CA), gestational age (GA), antenatal steroid exposure (ANS), birthweight (BW), weight at treatment initiation (WT), and PDA/left pulmonary artery (LPA) ratio. Study Design This is a single-center retrospective cohort study of preterm infants less than 37 weeks' GA born January 1, 2016 to December 31, 2018 who received acetaminophen and/or indomethacin for PDA treatment. Cox proportional hazards regression models were used to determine whether factors of interest were associated with PDA response to medical treatment. Results In total, 289 treatment courses were administered to 132 infants. Thirty-one (23%) infants experienced treatment-associated PDA closure. Ninety-four (71%) infants had evidence of PDA constriction following any treatment course. Ultimately, 84 (64%) infants experienced definitive PDA closure. For each 7-day increase in CA at the time of treatment initiation, the PDA was 59% less likely to close (p = 0.04) and 42% less likely to respond (i.e., constrict or close) to treatment (p < 0.01). PDA/LPA ratio was associated with treatment-associated PDA closure (p = 0.01). For every 0.1 increase in the PDA/LPA ratio, the PDA was 19% less likely to close in response to treatment. Conclusion In this cohort, PDA closure is independent of PMA, GA, ANS, BW, and WT; however, CA at treatment initiation predicted both treatment-associated PDA closure and PDA response (i.e., constriction or closure), and PDA/LPA ratio was associated with treatment-associated closure. Most infants experienced PDA constriction rather than closure, despite receiving up to four treatment courses. Key PointsKeywords
This publication has 31 references indexed in Scilit:
- Comparison of Oral Paracetamol versus Ibuprofen in Premature Infants with Patent Ductus Arteriosus: A Randomized Controlled TrialPLOS ONE, 2013
- Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3Archives of Disease in Childhood - Fetal and Neonatal Edition, 2013
- Patent ductus arteriosus: to treat or not to treat?Archives of Disease in Childhood - Fetal and Neonatal Edition, 2011
- Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?Journal of Perinatology, 2010
- Ibuprofen in very preterm infants impairs renal function for the first month of lifePediatric Nephrology, 2010
- Failure of Ductus Arteriosus Closure Is Associated With Increased Mortality in Preterm InfantsPediatrics, 2009
- Factors affecting successful closure of hemodynamically significant patent ductus arteriosus with indomethacin in extremely low birth weight infantsWorld Journal of Pediatrics, 2008
- Risk Factors for Persistent Ductus Arteriosus Patency during Indomethacin TreatmentThe Journal of Pediatrics, 2007
- New insights into spontaneous intestinal perforation using a national data set: (1) SIP is associated with early indomethacin exposureJournal of Perinatology, 2005
- Early echocardiographic prediction of symptomatic patent ductus arteriosus in preterm infants undergoing mechanical ventilationThe Journal of Pediatrics, 1995